$CCEL
CRYO CELL INTERNATIONAL INC

2017 Q4 Form 10-K Financial Statement

#000119312519057945 Filed on February 28, 2019

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $6.470M $25.38M $5.870M
YoY Change 10.22% 9.76% 1.21%
Cost Of Revenue $1.640M $6.724M $1.440M
YoY Change 13.89% 16.44% -2.04%
Gross Profit $4.840M $18.66M $4.430M
YoY Change 9.26% 7.53% 2.31%
Gross Profit Margin 74.81% 73.51% 75.47%
Selling, General & Admin $3.540M $13.48M $3.810M
YoY Change -7.09% -8.44% -0.78%
% of Gross Profit 73.14% 72.25% 86.0%
Research & Development $20.00K $41.17K $20.00K
YoY Change 0.0% -22.47% 100.0%
% of Gross Profit 0.41% 0.22% 0.45%
Depreciation & Amortization $60.00K $230.0K $70.00K
YoY Change -14.29% -5.35% 0.0%
% of Gross Profit 1.24% 1.23% 1.58%
Operating Expenses $3.590M $13.52M $3.860M
YoY Change -6.99% -8.49% -0.77%
Operating Profit $1.250M $5.006M $570.0K
YoY Change 119.3% 1054.59% 29.55%
Interest Expense -$370.0K $1.303M -$140.0K
YoY Change 164.29% 37.51% -50.0%
% of Operating Profit -29.6% 26.02% -24.56%
Other Income/Expense, Net -$20.00K -$1.383M $30.00K
YoY Change -166.67% -52.55% 0.0%
Pretax Income $860.0K $3.624M $350.0K
YoY Change 145.71% -246.1% -170.0%
Income Tax $180.0K $1.309M -$460.0K
% Of Pretax Income 20.93% 36.11% -131.43%
Net Earnings $680.0K $2.315M $810.0K
YoY Change -16.05% -275.28% -468.18%
Net Earnings / Revenue 10.51% 9.12% 13.8%
Basic Earnings Per Share $0.33
Diluted Earnings Per Share $89.24K $0.30 $118.9K
COMMON SHARES
Basic Shares Outstanding 7.103M shares 7.063M shares 6.796M shares
Diluted Shares Outstanding 7.653M shares

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.720M $6.718M $4.120M
YoY Change 63.11% 62.91% -13.45%
Cash & Equivalents $6.279M $6.279M $3.500M
Short-Term Investments $440.0K $439.3K $620.0K
Other Short-Term Assets $206.1K $578.3K $78.45K
YoY Change 162.77% 22.01% -11.25%
Inventory $314.6K $314.6K $361.1K
Prepaid Expenses $372.2K $395.5K
Receivables $5.126M $5.126M $4.053M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.74M $12.74M $9.012M
YoY Change 41.33% 41.33% -12.95%
LONG-TERM ASSETS
Property, Plant & Equipment $882.4K $882.4K $979.5K
YoY Change -9.91% -9.91% 11.42%
Goodwill $0.00 $0.00
YoY Change -100.0%
Intangibles $226.4K $261.0K
YoY Change -13.25% -49.45%
Long-Term Investments $0.00
YoY Change
Other Assets $10.29M $10.06M $9.547M
YoY Change 7.79% 8.38% 15.5%
Total Long-Term Assets $11.17M $11.17M $10.53M
YoY Change 6.14% 6.14% 15.11%
TOTAL ASSETS
Total Short-Term Assets $12.74M $12.74M $9.012M
Total Long-Term Assets $11.17M $11.17M $10.53M
Total Assets $23.91M $23.91M $19.54M
YoY Change 22.37% 22.37% 0.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.929M $1.929M $1.485M
YoY Change 29.83% 29.83% 11.8%
Accrued Expenses $2.582M $2.582M $2.554M
YoY Change 1.1% 1.1% 27.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M $2.000M
YoY Change 0.0% 0.0% 545.16%
Total Short-Term Liabilities $13.94M $13.94M $13.11M
YoY Change 6.32% 6.32% 25.78%
LONG-TERM LIABILITIES
Long-Term Debt $1.425M $5.295M $1.425M
YoY Change 0.0% -32.28% -38.04%
Other Long-Term Liabilities $22.47M $17.18M $21.84M
YoY Change 2.89% 22.51% 55.58%
Total Long-Term Liabilities $23.90M $22.47M $23.27M
YoY Change 2.72% 2.89% 42.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.94M $13.94M $13.11M
Total Long-Term Liabilities $23.90M $22.47M $23.27M
Total Liabilities $36.41M $36.41M $34.95M
YoY Change 4.18% 4.18% 42.89%
SHAREHOLDERS EQUITY
Retained Earnings -$24.47M -$26.79M
YoY Change -8.64% 5.19%
Common Stock $31.50M $30.47M
YoY Change 3.4% 6.33%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.57M $19.12M
YoY Change 2.34% 129.91%
Treasury Stock Shares 5.801M shares 5.715M shares
Shareholders Equity -$12.50M -$12.50M -$15.41M
YoY Change
Total Liabilities & Shareholders Equity $23.91M $23.91M $19.54M
YoY Change 22.37% 22.37% 0.21%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income $680.0K $2.315M $810.0K
YoY Change -16.05% -275.28% -468.18%
Depreciation, Depletion And Amortization $60.00K $230.0K $70.00K
YoY Change -14.29% -5.35% 0.0%
Cash From Operating Activities $2.110M $5.718M $2.570M
YoY Change -17.9% 14.64% 29.15%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $98.33K -$40.00K
YoY Change 0.0% -71.33% -33.33%
Acquisitions
YoY Change
Other Investing Activities $30.00K $191.4K -$30.00K
YoY Change -200.0% -815.36% -83.33%
Cash From Investing Activities -$20.00K $93.03K -$70.00K
YoY Change -71.43% -125.16% -70.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $446.6K
YoY Change -95.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -480.0K -3.032M -1.020M
YoY Change -52.94% -42.47% 218.75%
NET CHANGE
Cash From Operating Activities 2.110M 5.718M 2.570M
Cash From Investing Activities -20.00K 93.03K -70.00K
Cash From Financing Activities -480.0K -3.032M -1.020M
Net Change In Cash 1.610M 2.779M 1.480M
YoY Change 8.78% -526.09% 3.5%
FREE CASH FLOW
Cash From Operating Activities $2.110M $5.718M $2.570M
Capital Expenditures -$40.00K $98.33K -$40.00K
Free Cash Flow $2.150M $5.620M $2.610M
YoY Change -17.62% 20.99% 27.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000 shares
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000 shares
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000 shares
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7803333 shares
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000 shares
CY2018Q2 dei Entity Public Float
EntityPublicFloat
30604058
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2278862
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3499881
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-15414258
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2582475
CY2017Q4 us-gaap Assets Current
AssetsCurrent
12736921
CY2017Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
424782
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
356483
CY2017Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1068381
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2098991
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5125591
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
84555
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6566846
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
31373048
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1928542
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
40865
CY2017Q4 us-gaap Assets
Assets
23909997
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6279154
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7103941 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12899517 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
128995
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5886000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
405000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1039000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2316000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10036000
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
10035388
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7428829
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12356000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
0
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15752864
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
711000
CY2017Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
12000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
226418
CY2017Q4 us-gaap Goodwill
Goodwill
0
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
226418
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
210854
CY2017Q4 us-gaap Inventory Net
InventoryNet
314566
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
97210
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
648274
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13939846
CY2017Q4 us-gaap Liabilities
Liabilities
36412893
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23909997
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
7295183
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5295183
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2000000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
439322
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
206136
CY2017Q4 us-gaap Notes Payable
NotesPayable
7500100
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10290694
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
372152
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22473047
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
882382
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7449228
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24474691
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
39168 shares
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.41
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086 shares
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
204917
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12502896
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2017Q4 ccel Inventory Collection Kits
InventoryCollectionKits
14220
CY2017Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
8000
CY2017Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1909000
CY2017Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1788000
CY2017Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
28888
CY2017Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
18000
CY2017Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
618000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2702788
CY2018Q4 us-gaap Assets Current
AssetsCurrent
29535210
CY2018Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
478449
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
323792
CY2018Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1021004
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2264848
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
14867
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6807482
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35515382
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1261653
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
340984
CY2018Q4 us-gaap Assets
Assets
42390143
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
4282975
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7800833 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13596409 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
135964
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
191000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5157000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
257000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
868000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1634000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
7657000
CY2018Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7656897
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8365284
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9482000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
18000
CY2018Q4 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
20317231
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
330000
CY2018Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
112000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
92081
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
76343
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
76343
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
76343
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
76343
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1341336
CY2018Q4 us-gaap Goodwill
Goodwill
1941411
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1341336
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5262
CY2018Q4 us-gaap Inventory Net
InventoryNet
16035873
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
188085
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
864676
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429725
CY2018Q4 us-gaap Liabilities
Liabilities
51298441
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42390143
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
12943510
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
3100000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3100000
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3100000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3100000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
808433
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9843510
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
875689
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
254465
CY2018Q4 us-gaap Notes Payable
NotesPayable
13208433
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
18832
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
225984
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11361532
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
227368
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
461815
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35868716
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1493401
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8300883
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25329515
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
40254 shares
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.06
CY2018Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.58
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086 shares
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
264923
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
961111 shares
CY2017 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-1019453
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1001365 shares
CY2018Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.77
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2018Q4 ccel Inventory Collection Kits
InventoryCollectionKits
19163
CY2018Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
-79000
CY2018Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1210000
CY2018Q4 ccel Finite Lived Intangible Assets Amortization Expense Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseThereafter
943883
CY2018Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1214000
CY2018Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
113888
CY2018Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
18000
CY2018Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
428000
CY2018Q4 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2 CompensationPlan
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2014Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2014Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600 sqft
CY2018Q3 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600 sqft
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2016 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
972000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
744233
CY2017 us-gaap Adjustment For Amortization
AdjustmentForAmortization
229995
CY2017 us-gaap Advertising Expense
AdvertisingExpense
1008000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
487350
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
971730
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
125434
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2017 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.14
CY2017 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
30649232
CY2017 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.14
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2779273
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2321557
CY2017 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
98000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1483000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
108000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2074000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
483000
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1195183
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-73000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6724391
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
20378053
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-318000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-765000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-447000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
178645
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3513477
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
118640
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1149875
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
28145
CY2017 us-gaap Interest Expense
InterestExpense
1302650
CY2017 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
571873
CY2017 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-774806
CY2017 us-gaap Depreciation
Depreciation
230000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
131614
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3722 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0309 pure
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-46576
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-23349
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0000 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0508 pure
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0000 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0337 pure
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3623703
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1308603
CY2017 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
108481
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
443112
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
127688
CY2017 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
590114 shares
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
446439
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
310970
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1382523
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
93025
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3031925
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5718173
CY2017 us-gaap Net Income Loss
NetIncomeLoss
2315100
CY2017 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6457
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-79873
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
5006226
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2650000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
77012
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41165
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
25384279
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
971730
CY2017 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.0975 pure
CY2017 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
0.000 pure
CY2017 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0452 pure
CY2017 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-191358
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
446621
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
98333
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64696
CY2017 us-gaap Profit Loss
ProfitLoss
2315100
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64696
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13480883
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
CY2017 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7652984 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7062870 shares
CY2017 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-82000
CY2017 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
446621
CY2017 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
589399
CY2017 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
3388
CY2017 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
108481
CY2017 ccel Income Tax Reconciliation Valuation Allowance Release
IncomeTaxReconciliationValuationAllowanceRelease
0
CY2017 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
-342645
CY2017 ccel Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
3100000
CY2017 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments
444000
CY2017 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
141000
CY2017 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
158780
CY2017 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
125434
CY2017 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.0309 pure
CY2017 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
478000
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
907263
CY2018 us-gaap Adjustment For Amortization
AdjustmentForAmortization
317326
CY2018 us-gaap Advertising Expense
AdvertisingExpense
986664
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
345637
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
478378
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
109292
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
76000
CY2018 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.36
CY2018 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
31388278
CY2018 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-415280
CY2018 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-2658679
CY2018 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.36
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Risks</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units.&#xA0;However, the Company believes that alternative sources of supply and manufacturing are available.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> During fiscal 2018 and 2017, there were no concentration of risks.</p> </div>
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-239121
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-554705
CY2018 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
Company depends on one supplier for the source of its collection kits
CY2018 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
137000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1467000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
108000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2197000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
622000
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8539662
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
24029187
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2716000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2275000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-441000
CY2018 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15 pure
CY2018 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
2378491
CY2018 us-gaap Depreciation
Depreciation
241000
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Type
DocumentType
10-K
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
180264
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.2363 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0299 pure
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2210 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0721 pure
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0599 pure
CY2018 dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-11-30
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.8508 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0009 pure
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-162307
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3617680
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4472504
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
3078094
CY2018 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
108314
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-666889
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
48329
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
799507
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
260845
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-711000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
216608
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4095416
CY2018 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Product Warranty and Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> Program</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#xA0;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#xA0;1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company&#x2019;s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company&#x2019;s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company&#x2019;s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of November&#xA0;30, 2018 and November&#xA0;30, 2017 the Company recorded reserves under these programs in the amounts of approximately $18,000 and $18,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.</p> </div>
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-3354
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1347773
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
120313
CY2018 us-gaap Interest Expense
InterestExpense
1546900
CY2018 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
698876
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-316650
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
20796
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
589583
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
312307
CY2018 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
20103661
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1571623
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11282411
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5709960
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5333330
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-854824
CY2018 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
300119
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24723
CY2018 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
1405406
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
5189303
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
169300
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
200000
CY2018 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
136248
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
446163
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
170925
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
9000000
CY2018 us-gaap Profit Loss
ProfitLoss
-854824
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3291665
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
727483
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91845
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29218490
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
478378
CY2018 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y11M19D
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3670925
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15632696
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.73
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
51636 shares
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
50550 shares
CY2018 dei Trading Symbol
TradingSymbol
CCEL
CY2018 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0 shares
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7463051 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7463051 shares
CY2018 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-28000
CY2018 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2018 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
671245
CY2018 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
85000
CY2018 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
108314
CY2018 ccel Income Tax Reconciliation Valuation Allowance Release
IncomeTaxReconciliationValuationAllowanceRelease
0
CY2018 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
-28337
CY2018 ccel Allocated Share Based Compensation Expenses Reversed
AllocatedShareBasedCompensationExpensesReversed
444000
CY2018 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
158000
CY2018 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
149141
CY2018 ccel Increase Decrease In Goodwill
IncreaseDecreaseInGoodwill
66565
CY2018 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
109293
CY2018 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000 shares
CY2018 ccel Contracted Storage Period Option Three
ContractedStoragePeriodOptionThree
Lifetime
CY2018 ccel Number Of License Agreement
NumberOfLicenseAgreement
2 Agreement
CY2018 ccel Number Of Licensing Agreement Made By Entity
NumberOfLicensingAgreementMadeByEntity
12 Agreement
CY2018 ccel Types Of License Agreements
TypesOfLicenseAgreements
2 Agreement
CY2018 ccel Number Of Deliverables For Revenue Recognized
NumberOfDeliverablesForRevenueRecognized
2 Deliverables
CY2018 ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P21Y
CY2018 ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2018 ccel Contracted Storage Period Option One
ContractedStoragePeriodOptionOne
P1Y
CY2018 ccel Contracted Storage Period Option Two
ContractedStoragePeriodOptionTwo
P21Y
CY2018 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.0078 pure
CY2018 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
0.000 pure
CY2018 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0412 pure
CY2018 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.0299 pure
CY2018 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure

Files In Submission

Name View Source Status
0001193125-19-057945-index-headers.html Edgar Link pending
0001193125-19-057945-index.html Edgar Link pending
0001193125-19-057945.txt Edgar Link pending
0001193125-19-057945-xbrl.zip Edgar Link pending
ccel-20181130.xml Edgar Link completed
ccel-20181130.xsd Edgar Link pending
ccel-20181130_cal.xml Edgar Link unprocessable
ccel-20181130_def.xml Edgar Link unprocessable
ccel-20181130_lab.xml Edgar Link unprocessable
ccel-20181130_pre.xml Edgar Link unprocessable
d653307d10k.htm Edgar Link pending
d653307dex311.htm Edgar Link pending
d653307dex312.htm Edgar Link pending
d653307dex313.htm Edgar Link pending
d653307dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g653307g0227135741772.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending